William Blair analyst Sami Corwin downgraded Cargo Therapeutics (CRGX) to Market Perform from Outperform without a price target after the company announced the discontinuation of the Phase II FIRCE-1 clinical trial of its lead autologous CD22 CAR-T candidate firi-cel after an ad hoc analysis prompted by recent safety events found an unfavorable benefit/risk profile.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRGX:
- Cargo Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Cargo Therapeutics downgraded to Hold from Buy at Jefferies
- Cargo Therapeutics downgraded to Neutral from Buy at Chardan
- Cargo Therapeutics to discontinue FIRCE-1 Phase 2 study of Firi-cel
- Closing Bell Movers: Microsoft down 5%, Tesla up 4% after earnings